Odense, Denmark, 2 February 2009. Proxeon A/S (Proxeon) today announced that it has successfully completed a capital increase of DKK 14 Million. The investment was made by current venture capital investors as well as several members of the board.

The proceeds, which are expected to be sufficient to reach positive cash flow, will be used to continue building Proxeon’s position in the global proteomics market. For the financial year 2008, Proxeon will be reporting revenue growth in excess of 60%.

“We are excited to note our shareholders’ level of commitment which will enable the company to continue expansion in the years to come” stated Mårten Winge, CEO at Proxeon.

Mr. Winge continued, “Since launch in 2006, we have shipped more than 100 of our novel EASY-nLCTM systems for nanoscale chromatography to leading proteomics laboratories around the world. Of particular note was the decision made by the Max Planck Institute in Martinsried, Germany to replace and standardize all their nano LC instruments with EASY-nLC systems. This has been a stellar year for us. With a rapidly growing demand we are now well positioned to become the leader in this market place. The additional resources will help us accelerate towards this goal.”

Mårten Winge, CEO at Proxeon, added: “Mr. Eng has worked in leading proteomics laboratories and been closely involved in the development of software tools for MS data analysis for many years. We are delighted that Mr. Eng and UWPR have confidence in the benefits of ProteinCenter as an important tool in the interpretation of complex proteomics data.”